{
    "xml": "<topic id=\"PHP2939\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/lamotrigine\" basename=\"lamotrigine\" title=\"LAMOTRIGINE\">\n<title>LAMOTRIGINE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_283\" namespace=\"/interactions/list-of-drug-interactions/antiepileptics/lamotrigine\">Lamotrigine</xref>\n</p>\n<data name=\"vtmid\">96195007</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_926692410\" title=\"Antiepileptics\">Antiepileptics</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">   </data>\n</data>\r\n</body>\n<topic id=\"PHP72850\" outputclass=\"indicationsAndDose\" rev=\"1.45\" parent=\"/drugs/lamotrigine\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Monotherapy of focal seizures</p>\n<p outputclass=\"therapeuticIndication\">Monotherapy of primary and secondary generalised tonic-clonic seizures</p>\n<p outputclass=\"therapeuticIndication\">Monotherapy of seizures associated with Lennox-Gastaut syndrome</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 25&#8239;mg once daily for 14 days, then increased to 50&#8239;mg once daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses; increased if necessary up to 500&#8239;mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8239;mg once daily for 14 days, then increased to 50&#8239;mg once daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses; increased if necessary up to 500&#8239;mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of focal seizures with valproate</p>\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of primary and secondary generalised tonic-clonic seizures with valproate</p>\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome with valproate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 2&#8211;11 years (body-weight up to 13 kg)</p>\n<p>Initially 2&#8239;mg once daily on alternate days for first 14 days, then 300&#8239;micrograms/kg once daily for further 14 days, then increased in steps of up to 300&#8239;micrograms/kg every 7&#8211;14&#8239;days; maintenance 1&#8211;5&#8239;mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 2&#8211;11 years (body-weight 13 kg and above)</p>\n<p>Initially 150&#8239;micrograms/kg once daily for 14 days, then 300&#8239;micrograms/kg once daily for further 14 days, then increased in steps of up to 300&#8239;micrograms/kg every 7&#8211;14&#8239;days; maintenance 1&#8211;5&#8239;mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 25&#8239;mg once daily on alternate days for 14 days, then 25&#8239;mg once daily for further 14 days, then increased in steps of up to 50&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8239;mg once daily on alternate days for 14 days, then 25&#8239;mg once daily for further 14 days, then increased in steps of up to 50&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of focal seizures (with enzyme inducing drugs) without valproate</p>\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of primary and secondary generalised tonic-clonic seizures (with enzyme inducing drugs) without valproate</p>\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of seizures associated with Lennox-Gastaut syndromes (with enzyme inducing drugs) without valproate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 2&#8211;11 years</p>\n<p>Initially 300&#8239;micrograms/kg twice daily for 14 days, then 600&#8239;micrograms/kg twice daily for further 14 days, then increased in steps of up to 1.2&#8239;mg/kg every 7&#8211;14&#8239;days; maintenance 5&#8211;15&#8239;mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 50&#8239;mg once daily for 14 days, then 50&#8239;mg twice daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 200&#8211;400&#8239;mg daily in 2 divided doses, increased if necessary up to 700&#8239;mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 50&#8239;mg once daily for 14 days, then 50&#8239;mg twice daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 200&#8211;400&#8239;mg daily in 2 divided doses, increased if necessary up to 700&#8239;mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of focal seizures (without enzyme inducing drugs) without valproate</p>\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of primary and secondary generalised tonic-clonic seizures (without enzyme inducing drugs) without valproate</p>\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of seizures associated with Lennox-Gastaut syndromes (without enzyme inducing drugs) without valproate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup child\">\n<p>Child 2&#8211;11 years</p>\n<p>Initially 300&#8239;micrograms/kg daily in 1&#8211;2 divided doses for 14 days, then 600&#8239;micrograms/kg daily in 1&#8211;2 divided doses for further 14 days, then increased in steps of up to 600&#8239;micrograms/kg every 7&#8211;14&#8239;days; maintenance 1&#8211;10&#8239;mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200&#8239;mg per day.</p>\n</li>\n<li outputclass=\"patientGroup child\">\n<p>Child 12&#8211;17 years</p>\n<p>Initially 25&#8239;mg once daily for 14 days, then increased to 50&#8239;mg once daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8239;mg once daily for 14 days, then increased to 50&#8239;mg once daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Monotherapy or adjunctive therapy of bipolar disorder (without enzyme inducing drugs) without valproate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8239;mg once daily for 14 days, then 50&#8239;mg daily in 1&#8211;2 divided doses for further 14 days, then 100&#8239;mg daily in 1&#8211;2 divided doses for further 7 days; maintenance 200&#8239;mg daily in 1&#8211;2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of bipolar disorder with valproate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 25&#8239;mg once daily on alternate days for 14 days, then 25&#8239;mg once daily for further 14 days, then 50&#8239;mg daily in 1&#8211;2 divided doses for further 7 days; maintenance 100&#8239;mg daily in 1&#8211;2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200&#8239;mg per day.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Adjunctive therapy of bipolar disorder (with enzyme inducing drugs) without valproate</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>Initially 50&#8239;mg once daily for 14 days, then 50&#8239;mg twice daily for further 14 days, then increased to 100&#8239;mg twice daily for further 7 days, then increased to 150&#8239;mg twice daily for further 7 days; maintenance 200&#8239;mg twice daily, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72992\" outputclass=\"importantSafetyInformation\" rev=\"1.11\" parent=\"/drugs/lamotrigine\">\n<title>Important safety information</title>\n<body>\n<section>\n<sectiondiv>\n<p outputclass=\"title\">Safe Practice</p>\n<p>Do not confuse the different combinations or indications.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73010\" outputclass=\"cautions\" rev=\"1.18\" parent=\"/drugs/lamotrigine\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Myoclonic seizures (may be exacerbated)</ph>; <ph outputclass=\"caution\">Parkinson&#8217;s disease (may be exacerbated)</ph> (in adults)</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72841\" outputclass=\"interactions\" rev=\"1.12\" parent=\"/drugs/lamotrigine\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (lamotrigine).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72813\" outputclass=\"sideEffects\" rev=\"1.12\" parent=\"/drugs/lamotrigine\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Blurred vision</ph>; <ph outputclass=\"sideEffect\">aggression</ph>; <ph outputclass=\"sideEffect\">agitation</ph>; <ph outputclass=\"sideEffect\">arthralgia</ph>; <ph outputclass=\"sideEffect\">ataxia</ph>; <ph outputclass=\"sideEffect\">back pain</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">diplopia</ph>; <ph outputclass=\"sideEffect\">dizziness</ph>; <ph outputclass=\"sideEffect\">drowsiness</ph>; <ph outputclass=\"sideEffect\">dry mouth</ph>; <ph outputclass=\"sideEffect\">headache</ph>; <ph outputclass=\"sideEffect\">insomnia</ph>; <ph outputclass=\"sideEffect\">nausea</ph>; <ph outputclass=\"sideEffect\">nystagmus</ph>; <ph outputclass=\"sideEffect\">rash</ph>; <ph outputclass=\"sideEffect\">tremor</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"rare\">\n<p outputclass=\"title\">Rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Conjunctivitis</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"veryRare\">\n<p outputclass=\"title\">Very rare</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Anaemia</ph>; <ph outputclass=\"sideEffect\">blood disorders</ph>; <ph outputclass=\"sideEffect\">confusion</ph>; <ph outputclass=\"sideEffect\">exacerbation of Parkinson&#8217;s disease</ph> (in adults); <ph outputclass=\"sideEffect\">hallucination</ph>; <ph outputclass=\"sideEffect\">hepatic failure</ph>; <ph outputclass=\"sideEffect\">hypersensitivity syndrome</ph>; <ph outputclass=\"sideEffect\">increase in seizure frequency</ph>; <ph outputclass=\"sideEffect\">leucopenia</ph>; <ph outputclass=\"sideEffect\">lupus erythematosus-like reactions</ph>; <ph outputclass=\"sideEffect\">movement disorders</ph>; <ph outputclass=\"sideEffect\">pancytopenia</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">unsteadiness</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"notKnown\">\n<p outputclass=\"title\">Frequency not known</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Aseptic meningitis</ph>; <ph outputclass=\"sideEffect\">suicidal ideation</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p outputclass=\"title\">Skin reactions</p>\n<p>Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed (especially in children); most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP73021\" outputclass=\"allergyAndCrossSensitivity\" rev=\"1.37\" parent=\"/drugs/lamotrigine\">\n<title>Allergy and cross-sensitivity</title>\n<body>\r\n\r\n<section outputclass=\"allergyAndCrossSensitivityCrossSensitivity\">\r\n<sectiondiv>\r\n<p>Antiepileptic hypersensitivity syndrome associated with lamotrigine. See under <xref format=\"dita\" href=\"#PHP78230\" type=\"bookmark\" namespace=\"/treatment-summaries/epilepsy\">Epilepsy</xref> for more information.</p>\n</sectiondiv>\n</section>\r\n</body>\n</topic>\n<topic id=\"PHP73014\" outputclass=\"breastFeeding\" parent=\"/drugs/lamotrigine\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Present in milk, but limited data suggest no harmful effect on infant.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72978\" outputclass=\"hepaticImpairment\" parent=\"/drugs/lamotrigine\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Halve dose in moderate impairment.</p>\n<p>Quarter dose in severe impairment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72827\" outputclass=\"renalImpairment\" parent=\"/drugs/lamotrigine\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>Consider reducing maintenance dose in significant impairment.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Caution in renal failure; metabolite may accumulate.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72802\" outputclass=\"treatmentCessation\" rev=\"1.13\" parent=\"/drugs/lamotrigine\">\n<title>Treatment cessation</title>\n<body>\n<section>\n<sectiondiv>\n<p>Avoid abrupt withdrawal (taper off over 2 weeks or longer) unless serious skin reaction occurs.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57690\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.11\" parent=\"/drugs/lamotrigine\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Patients being treated for epilepsy may need to be maintained on a specific manufacturer&#8217;s branded or generic lamotrigine product.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Switching between formulations</p>\n<p>Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP72830\" outputclass=\"patientAndCarerAdvice\" rev=\"1.25\" parent=\"/drugs/lamotrigine\">\n<title>Patient and carer advice</title>\n<body>\r\n\r\n\r\n<section outputclass=\"patientResources\">\r\n<sectiondiv>\r\n<p outputclass=\"specificity\">In children</p>\r\n<p outputclass=\"title\">Medicines for Children leaflet: Lamotrigine for preventing seizures</p>\r\n<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/lamotrigine-for-preventing-seizures\">www.medicinesforchildren.org.uk/lamotrigine-for-preventing-seizures</xref>\n</p>\n</sectiondiv>\n</section>\r\n<section outputclass=\"generalPatientAdvice\">\r\n<sectiondiv>\r\n<p outputclass=\"title\">Skin reactions</p>\r\n<p>Warn patients and carers to see their doctor immediately if rash or signs or symptoms of hypersensitivity syndrome develop.</p>\n</sectiondiv>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Blood disorders</p>\r\n<p>Patients and their carers should be alert for symptoms and signs suggestive of bone-marrow failure, such as anaemia, bruising, or infection. Aplastic anaemia, bone-marrow depression, and pancytopenia have been associated rarely with lamotrigine.</p>\n</sectiondiv>\n</section>\r\n\r\n\r\n\r\n\r\n\r\n</body>\n</topic>\n<topic id=\"PHP2939-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/lamotrigine\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n<p>Forms available from special-order manufacturers include: oral solution, oral suspension</p>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76356\" title=\"Tablet\" namespace=\"/drugs/lamotrigine/tablet\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76363\" title=\"Dispersible tablet\" namespace=\"/drugs/lamotrigine/dispersible-tablet\">Dispersible tablet</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_283\" namespace=\"/interactions/list-of-drug-interactions/antiepileptics/lamotrigine\" title=\"Lamotrigine\" count=\"1\" rel=\"link\">Lamotrigine</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78230\" namespace=\"/treatment-summaries/epilepsy\" title=\"Epilepsy\" count=\"1\" rel=\"link\">Epilepsy</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76356\" namespace=\"/drugs/lamotrigine/tablet\" title=\"Tablet\" count=\"1\" rel=\"link\">Tablet</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP76363\" namespace=\"/drugs/lamotrigine/dispersible-tablet\" title=\"Dispersible tablet\" count=\"1\" rel=\"link\">Dispersible tablet</xref>\n</links>\n</topic>",
    "id": "PHP2939",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/lamotrigine",
    "basename": "lamotrigine",
    "title": "LAMOTRIGINE",
    "interactants": [
        {
            "id": "bnf_int_283",
            "label": "Lamotrigine"
        }
    ],
    "vtmid": "96195007",
    "drugClassification": [
        "Antiepileptics"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Monotherapy of focal seizures",
                        "html": "Monotherapy of focal seizures"
                    },
                    {
                        "textContent": "Monotherapy of primary and secondary generalised tonic-clonic seizures",
                        "html": "Monotherapy of primary and secondary generalised tonic-clonic seizures"
                    },
                    {
                        "textContent": "Monotherapy of seizures associated with Lennox-Gastaut syndrome",
                        "html": "Monotherapy of seizures associated with Lennox-Gastaut syndrome"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses; increased if necessary up to 500 mg daily, dose titration should be repeated if restarting after interval of more than 5 days.",
                        "html": "<p>Initially 25&#8239;mg once daily for 14 days, then increased to 50&#8239;mg once daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses; increased if necessary up to 500&#8239;mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses; increased if necessary up to 500 mg daily, dose titration should be repeated if restarting after interval of more than 5 days.",
                        "html": "<p>Initially 25&#8239;mg once daily for 14 days, then increased to 50&#8239;mg once daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses; increased if necessary up to 500&#8239;mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunctive therapy of focal seizures with valproate",
                        "html": "Adjunctive therapy of focal seizures with valproate"
                    },
                    {
                        "textContent": "Adjunctive therapy of primary and secondary generalised tonic-clonic seizures with valproate",
                        "html": "Adjunctive therapy of primary and secondary generalised tonic-clonic seizures with valproate"
                    },
                    {
                        "textContent": "Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome with valproate",
                        "html": "Adjunctive therapy of seizures associated with Lennox-Gastaut syndrome with valproate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "Initially 2 mg once daily on alternate days for first 14 days, then 300 micrograms/kg once daily for further 14 days, then increased in steps of up to 300 micrograms/kg every 7&#8211;14 days; maintenance 1&#8211;5 mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day.",
                        "html": "<p>Initially 2&#8239;mg once daily on alternate days for first 14 days, then 300&#8239;micrograms/kg once daily for further 14 days, then increased in steps of up to 300&#8239;micrograms/kg every 7&#8211;14&#8239;days; maintenance 1&#8211;5&#8239;mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200&#8239;mg per day.</p>",
                        "ageGroup": "2&#8211;11 years (body-weight up to 13 kg)"
                    },
                    {
                        "textContent": "Initially 150 micrograms/kg once daily for 14 days, then 300 micrograms/kg once daily for further 14 days, then increased in steps of up to 300 micrograms/kg every 7&#8211;14 days; maintenance 1&#8211;5 mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day.",
                        "html": "<p>Initially 150&#8239;micrograms/kg once daily for 14 days, then 300&#8239;micrograms/kg once daily for further 14 days, then increased in steps of up to 300&#8239;micrograms/kg every 7&#8211;14&#8239;days; maintenance 1&#8211;5&#8239;mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200&#8239;mg per day.</p>",
                        "ageGroup": "2&#8211;11 years (body-weight 13 kg and above)"
                    },
                    {
                        "textContent": "Initially 25 mg once daily on alternate days for 14 days, then 25 mg once daily for further 14 days, then increased in steps of up to 50 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.",
                        "html": "<p>Initially 25&#8239;mg once daily on alternate days for 14 days, then 25&#8239;mg once daily for further 14 days, then increased in steps of up to 50&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 25 mg once daily on alternate days for 14 days, then 25 mg once daily for further 14 days, then increased in steps of up to 50 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.",
                        "html": "<p>Initially 25&#8239;mg once daily on alternate days for 14 days, then 25&#8239;mg once daily for further 14 days, then increased in steps of up to 50&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunctive therapy of focal seizures (with enzyme inducing drugs) without valproate",
                        "html": "Adjunctive therapy of focal seizures (with enzyme inducing drugs) without valproate"
                    },
                    {
                        "textContent": "Adjunctive therapy of primary and secondary generalised tonic-clonic seizures (with enzyme inducing drugs) without valproate",
                        "html": "Adjunctive therapy of primary and secondary generalised tonic-clonic seizures (with enzyme inducing drugs) without valproate"
                    },
                    {
                        "textContent": "Adjunctive therapy of seizures associated with Lennox-Gastaut syndromes (with enzyme inducing drugs) without valproate",
                        "html": "Adjunctive therapy of seizures associated with Lennox-Gastaut syndromes (with enzyme inducing drugs) without valproate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "Initially 300 micrograms/kg twice daily for 14 days, then 600 micrograms/kg twice daily for further 14 days, then increased in steps of up to 1.2 mg/kg every 7&#8211;14 days; maintenance 5&#8211;15 mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400 mg per day.",
                        "html": "<p>Initially 300&#8239;micrograms/kg twice daily for 14 days, then 600&#8239;micrograms/kg twice daily for further 14 days, then increased in steps of up to 1.2&#8239;mg/kg every 7&#8211;14&#8239;days; maintenance 5&#8211;15&#8239;mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400&#8239;mg per day.</p>",
                        "ageGroup": "2&#8211;11 years"
                    },
                    {
                        "textContent": "Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 200&#8211;400 mg daily in 2 divided doses, increased if necessary up to 700 mg daily, dose titration should be repeated if restarting after interval of more than 5 days.",
                        "html": "<p>Initially 50&#8239;mg once daily for 14 days, then 50&#8239;mg twice daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 200&#8211;400&#8239;mg daily in 2 divided doses, increased if necessary up to 700&#8239;mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 200&#8211;400 mg daily in 2 divided doses, increased if necessary up to 700 mg daily, dose titration should be repeated if restarting after interval of more than 5 days.",
                        "html": "<p>Initially 50&#8239;mg once daily for 14 days, then 50&#8239;mg twice daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 200&#8211;400&#8239;mg daily in 2 divided doses, increased if necessary up to 700&#8239;mg daily, dose titration should be repeated if restarting after interval of more than 5 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunctive therapy of focal seizures (without enzyme inducing drugs) without valproate",
                        "html": "Adjunctive therapy of focal seizures (without enzyme inducing drugs) without valproate"
                    },
                    {
                        "textContent": "Adjunctive therapy of primary and secondary generalised tonic-clonic seizures (without enzyme inducing drugs) without valproate",
                        "html": "Adjunctive therapy of primary and secondary generalised tonic-clonic seizures (without enzyme inducing drugs) without valproate"
                    },
                    {
                        "textContent": "Adjunctive therapy of seizures associated with Lennox-Gastaut syndromes (without enzyme inducing drugs) without valproate",
                        "html": "Adjunctive therapy of seizures associated with Lennox-Gastaut syndromes (without enzyme inducing drugs) without valproate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "child": [
                    {
                        "textContent": "Initially 300 micrograms/kg daily in 1&#8211;2 divided doses for 14 days, then 600 micrograms/kg daily in 1&#8211;2 divided doses for further 14 days, then increased in steps of up to 600 micrograms/kg every 7&#8211;14 days; maintenance 1&#8211;10 mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day.",
                        "html": "<p>Initially 300&#8239;micrograms/kg daily in 1&#8211;2 divided doses for 14 days, then 600&#8239;micrograms/kg daily in 1&#8211;2 divided doses for further 14 days, then increased in steps of up to 600&#8239;micrograms/kg every 7&#8211;14&#8239;days; maintenance 1&#8211;10&#8239;mg/kg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200&#8239;mg per day.</p>",
                        "ageGroup": "2&#8211;11 years"
                    },
                    {
                        "textContent": "Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.",
                        "html": "<p>Initially 25&#8239;mg once daily for 14 days, then increased to 50&#8239;mg once daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</p>",
                        "ageGroup": "12&#8211;17 years"
                    }
                ],
                "adult": [
                    {
                        "textContent": "Initially 25 mg once daily for 14 days, then increased to 50 mg once daily for further 14 days, then increased in steps of up to 100 mg every 7&#8211;14 days; maintenance 100&#8211;200 mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.",
                        "html": "<p>Initially 25&#8239;mg once daily for 14 days, then increased to 50&#8239;mg once daily for further 14 days, then increased in steps of up to 100&#8239;mg every 7&#8211;14&#8239;days; maintenance 100&#8211;200&#8239;mg daily in 1&#8211;2 divided doses, dose titration should be repeated if restarting after interval of more than 5 days.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Monotherapy or adjunctive therapy of bipolar disorder (without enzyme inducing drugs) without valproate",
                        "html": "Monotherapy or adjunctive therapy of bipolar disorder (without enzyme inducing drugs) without valproate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 25 mg once daily for 14 days, then 50 mg daily in 1&#8211;2 divided doses for further 14 days, then 100 mg daily in 1&#8211;2 divided doses for further 7 days; maintenance 200 mg daily in 1&#8211;2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400 mg per day.",
                        "html": "<p>Initially 25&#8239;mg once daily for 14 days, then 50&#8239;mg daily in 1&#8211;2 divided doses for further 14 days, then 100&#8239;mg daily in 1&#8211;2 divided doses for further 7 days; maintenance 200&#8239;mg daily in 1&#8211;2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 400&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunctive therapy of bipolar disorder with valproate",
                        "html": "Adjunctive therapy of bipolar disorder with valproate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 25 mg once daily on alternate days for 14 days, then 25 mg once daily for further 14 days, then 50 mg daily in 1&#8211;2 divided doses for further 7 days; maintenance 100 mg daily in 1&#8211;2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200 mg per day.",
                        "html": "<p>Initially 25&#8239;mg once daily on alternate days for 14 days, then 25&#8239;mg once daily for further 14 days, then 50&#8239;mg daily in 1&#8211;2 divided doses for further 7 days; maintenance 100&#8239;mg daily in 1&#8211;2 divided doses, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days; maximum 200&#8239;mg per day.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Adjunctive therapy of bipolar disorder (with enzyme inducing drugs) without valproate",
                        "html": "Adjunctive therapy of bipolar disorder (with enzyme inducing drugs) without valproate"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "Initially 50 mg once daily for 14 days, then 50 mg twice daily for further 14 days, then increased to 100 mg twice daily for further 7 days, then increased to 150 mg twice daily for further 7 days; maintenance 200 mg twice daily, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days.",
                        "html": "<p>Initially 50&#8239;mg once daily for 14 days, then 50&#8239;mg twice daily for further 14 days, then increased to 100&#8239;mg twice daily for further 7 days, then increased to 150&#8239;mg twice daily for further 7 days; maintenance 200&#8239;mg twice daily, patients stabilised on lamotrigine for bipolar disorder may require dose adjustments if other drugs are added to or withdrawn from their treatment regimens&#8212;consult product literature, dose titration should be repeated if restarting after interval of more than 5 days.</p>"
                    }
                ]
            }
        ]
    },
    "importantSafetyInformation": {
        "importantSafetyInformation": [
            {
                "type": "importantSafetyInformation",
                "title": "Safe Practice",
                "textContent": "Do not confuse the different combinations or indications.",
                "html": "<p>Do not confuse the different combinations or indications.</p>"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Myoclonic seizures (may be exacerbated)",
                "html": "Myoclonic seizures (may be exacerbated)"
            },
            {
                "type": "cautions",
                "textContent": "Parkinson&#8217;s disease (may be exacerbated) in adults",
                "html": "Parkinson&#8217;s disease (may be exacerbated) in adults",
                "specificity": {
                    "patientType": "adults"
                }
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (lamotrigine).",
                "html": "<p>Appendix 1 (lamotrigine).</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Blurred vision",
                        "html": "Blurred vision",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "aggression",
                        "html": "aggression",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "agitation",
                        "html": "agitation",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "arthralgia",
                        "html": "arthralgia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "ataxia",
                        "html": "ataxia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "back pain",
                        "html": "back pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diplopia",
                        "html": "diplopia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dizziness",
                        "html": "dizziness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "drowsiness",
                        "html": "drowsiness",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dry mouth",
                        "html": "dry mouth",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "headache",
                        "html": "headache",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "insomnia",
                        "html": "insomnia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nystagmus",
                        "html": "nystagmus",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "rash",
                        "html": "rash",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "tremor",
                        "html": "tremor",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "rare": [
                    {
                        "type": "rare",
                        "textContent": "Conjunctivitis",
                        "html": "Conjunctivitis",
                        "frequency": "rare",
                        "specificity": {
                            "textContent": "Rare",
                            "html": "Rare"
                        }
                    }
                ],
                "veryRare": [
                    {
                        "type": "veryRare",
                        "textContent": "Anaemia",
                        "html": "Anaemia",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "blood disorders",
                        "html": "blood disorders",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "confusion",
                        "html": "confusion",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "exacerbation of Parkinson&#8217;s disease in adults",
                        "html": "exacerbation of Parkinson&#8217;s disease in adults",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare",
                            "patientType": "adults"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "hallucination",
                        "html": "hallucination",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "hepatic failure",
                        "html": "hepatic failure",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "hypersensitivity syndrome",
                        "html": "hypersensitivity syndrome",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "increase in seizure frequency",
                        "html": "increase in seizure frequency",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "leucopenia",
                        "html": "leucopenia",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "lupus erythematosus-like reactions",
                        "html": "lupus erythematosus-like reactions",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "movement disorders",
                        "html": "movement disorders",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "pancytopenia",
                        "html": "pancytopenia",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    },
                    {
                        "type": "veryRare",
                        "textContent": "unsteadiness",
                        "html": "unsteadiness",
                        "frequency": "veryRare",
                        "specificity": {
                            "textContent": "Very rare",
                            "html": "Very rare"
                        }
                    }
                ],
                "notKnown": [
                    {
                        "type": "notKnown",
                        "textContent": "Aseptic meningitis",
                        "html": "Aseptic meningitis",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    },
                    {
                        "type": "notKnown",
                        "textContent": "suicidal ideation",
                        "html": "suicidal ideation",
                        "frequency": "notKnown",
                        "specificity": {
                            "textContent": "Frequency not known",
                            "html": "Frequency not known"
                        }
                    }
                ]
            }
        },
        "advice": [
            {
                "type": "advice",
                "title": "Skin reactions",
                "textContent": "Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed (especially in children); most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.",
                "html": "<p>Serious skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have developed (especially in children); most rashes occur in the first 8 weeks. Rash is sometimes associated with hypersensitivity syndrome and is more common in patients with history of allergy or rash from other antiepileptic drugs. Consider withdrawal if rash or signs of hypersensitivity syndrome develop. Factors associated with increased risk of serious skin reactions include concomitant use of valproate, initial lamotrigine dosing higher than recommended, and more rapid dose escalation than recommended.</p>"
            }
        ]
    },
    "allergyAndCrossSensitivity": {
        "crossSensitivity": [
            {
                "type": "crossSensitivity",
                "references": [
                    {
                        "id": "PHP78230",
                        "label": "Epilepsy"
                    }
                ],
                "textContent": "Antiepileptic hypersensitivity syndrome associated with lamotrigine. See under Epilepsy for more information.",
                "html": "<p>Antiepileptic hypersensitivity syndrome associated with lamotrigine. See under <xref format=\"dita\" href=\"#PHP78230\" type=\"bookmark\" namespace=\"/treatment-summaries/epilepsy\">Epilepsy</xref> for more information.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Present in milk, but limited data suggest no harmful effect on infant.",
                "html": "<p>Present in milk, but limited data suggest no harmful effect on infant.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Halve dose in moderate impairment.\n\nQuarter dose in severe impairment.",
                "html": "<p>Halve dose in moderate impairment.</p><p>Quarter dose in severe impairment.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "Consider reducing maintenance dose in significant impairment.",
                "html": "<p>Consider reducing maintenance dose in significant impairment.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Caution in renal failure; metabolite may accumulate.",
                "html": "<p>Caution in renal failure; metabolite may accumulate.</p>"
            }
        ]
    },
    "treatmentCessation": {
        "treatmentCessation": [
            {
                "type": "treatmentCessation",
                "textContent": "Avoid abrupt withdrawal (taper off over 2 weeks or longer) unless serious skin reaction occurs.",
                "html": "<p>Avoid abrupt withdrawal (taper off over 2 weeks or longer) unless serious skin reaction occurs.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Patients being treated for epilepsy may need to be maintained on a specific manufacturer&#8217;s branded or generic lamotrigine product.",
                "html": "<p>Patients being treated for epilepsy may need to be maintained on a specific manufacturer&#8217;s branded or generic lamotrigine product.</p>"
            },
            {
                "type": "prescribingAndDispensingInformation",
                "title": "Switching between formulations",
                "textContent": "Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.",
                "html": "<p>Care should be taken when switching between oral formulations in the treatment of epilepsy. The need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with the patient or their carer, taking into account factors such as seizure frequency and treatment history.</p>"
            }
        ]
    },
    "patientAndCarerAdvice": {
        "patientResources": [
            {
                "type": "patientResources",
                "references": [
                    {
                        "id": "http://www.medicinesforchildren.org.uk/lamotrigine-for-preventing-seizures",
                        "label": "www.medicinesforchildren.org.uk/lamotrigine-for-preventing-seizures"
                    }
                ],
                "specificity": {
                    "textContent": "In children",
                    "html": "In children",
                    "patientType": "children"
                },
                "title": "Medicines for Children leaflet: Lamotrigine for preventing seizures",
                "textContent": "www.medicinesforchildren.org.uk/lamotrigine-for-preventing-seizures",
                "html": "<p>\n<xref format=\"html\" href=\"http://www.medicinesforchildren.org.uk/lamotrigine-for-preventing-seizures\">www.medicinesforchildren.org.uk/lamotrigine-for-preventing-seizures</xref>\n</p>"
            }
        ],
        "generalPatientAdvice": [
            {
                "type": "generalPatientAdvice",
                "title": "Skin reactions",
                "textContent": "Warn patients and carers to see their doctor immediately if rash or signs or symptoms of hypersensitivity syndrome develop.",
                "html": "<p>Warn patients and carers to see their doctor immediately if rash or signs or symptoms of hypersensitivity syndrome develop.</p>"
            },
            {
                "type": "generalPatientAdvice",
                "title": "Blood disorders",
                "textContent": "Patients and their carers should be alert for symptoms and signs suggestive of bone-marrow failure, such as anaemia, bruising, or infection. Aplastic anaemia, bone-marrow depression, and pancytopenia have been associated rarely with lamotrigine.",
                "html": "<p>Patients and their carers should be alert for symptoms and signs suggestive of bone-marrow failure, such as anaemia, bruising, or infection. Aplastic anaemia, bone-marrow depression, and pancytopenia have been associated rarely with lamotrigine.</p>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ],
        "availableForms": {
            "before": "Forms available from special-order manufacturers include",
            "forms": [
                "oral solution",
                "oral suspension"
            ]
        }
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP76356",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76363",
                "label": "Dispersible tablet",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_283",
                "label": "Lamotrigine",
                "type": "interaction"
            }
        ],
        "treatmentSummary": [
            {
                "id": "PHP78230",
                "label": "Epilepsy",
                "type": "treatmentSummary"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP76356",
                "label": "Tablet",
                "type": "medicinalForm"
            },
            {
                "id": "PHP76363",
                "label": "Dispersible tablet",
                "type": "medicinalForm"
            }
        ]
    }
}